People with periodontal disease have a 37% increased risk of developing anxiety, serious mental illness, and depression, and an 18% increased risk of developing cardiovascular disease.
Age-related macular degeneration and lupus share a common contributor to inflammation. The findings could help researchers develop new treatments for those conditions, and other conditions associated with inflammation.
Analyzing the gene activity of 66,000 cells from human brain tissue, researchers generated a comprehensive map of cell types associated with brain lesions in multiple sclerosis, and their gene expression patterns and interactions.
A new study links viral infections including mononucleosis and pneumonia experienced during adolescence with an increased risk of developing multiple sclerosis.
Piezo1 limits the potential of regulatory T cells (Treg) to mitigate autoimmune neuroinflammation. Inhibiting Piezo1 could lead to new treatments for autoimmune disorders like multiple sclerosis.
Scars and lesions on the brain and spinal cord offer clues as to why progressive disability occurs in patients with multiple sclerosis.
More frequent hospital and doctor's office visits in the years leading up to multiple sclerosis diagnosis with early MS type symptoms are usually associated with a prodromal phase of the disease, when they should be regarded as an ongoing progression of the autoimmune disorder.
Some of the T cell epitopes targeting myelin in monkeys were the same as those found in humans. Researchers say linking these specific cells opens the doors to developing antiviral therapies that could be useful to treat newly diagnosed cases of MS in humans.
Study finds signs of IgA antibodies in the cerebrospinal fluid of patients with multiple sclerosis during a flare-up of the disease, but not when the patients are in remission. The findings suggest gut immune cells are involved in relapse episodes of multiple sclerosis.
Poor sleep and inadequate oxygen supply associated with obstructive sleep apnea appears to affect cytokines. This could explain the link between OSA and an increased risk of autoimmune disorders, such as rheumatoid arthritis.
TEPP-46, a drug developed for the treatment of cancer and showed promise for the treatment of multiple sclerosis, could make MS symptoms worse, a new study reports. The drug appears to redirect inflammation away from the spinal cord and directly into the brain.
A new intranasal delivery system shows promise in reducing neuroinflammation and slowing the progression of multiple sclerosis.